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ABSTRACT 
  Pain management in terminally ill pets is an important and complex issue.  
Physical therapy, acupuncture, non-steroidal anti-inflammatory drugs, steroids, 
muscle relaxers, holistic herbs, nutraceuticals, cannabinoids, and opioids are all 
commonly used to manage their pain.  Often, they are used in combination with 
each other to better control the pain level.  Animal owners have the option of 
humane euthanasia which can be considered, when time, cost, or emotional toll 
goes beyond the benefit-cost value to a family.        
  This research demonstrates how to use a pain scale to facilitate decision 
making when managing chronic pain.  Some background on pain medications and 
other pain management modalities are discussed.  Normally more medications, 
higher doses, and opioids are added when pets are in a terminal decline. The 
research uses a terminally ill canine with cancer in the final six weeks of his life. 
We employ a benefit-cost analysis using pecuniary and non-pecuniary risks and 
benefits to facilitate a decision guide. The pecuniary variables are cost of 
medications and veterinary services. The non-pecuniary costs include separation 
anxiety and emotional cost. The satisfaction the pet owner gets from the 
companionship of the pet is captured as the principal benefit in the model.   
 The model explores alternative values for the different variables and 
simulates the potential decision outcomes. The decision rule using the benefit-cost 
ratio analysis is the traditional economic decision rule: When the benefit cost ratio 
is greater than unity, the pet owner may choose to continue treatment.  However, a 
benefit-cost ratio of less than unity would require the pet owner to consider the 
pet’s quality of life and discuss euthanasia as an effective economic and emotional 
option.  
        The benefit cost model developed in this study provides a useful tool for 
veterinarians to discuss the difficult subject of euthanasia with their clients when 
the quality of life of their terminally-ill pet does not justify sustaining life even if 
the pet owner’s separation anxiety seems to ignore this.  The model relieves the 
veterinarian from making the decision for the client, and allows the client to explore 
the relative weights they place on the different dimensions of the model to arrive at 
a decision that both humane and economical.   
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CHAPTER I: INTRODUCTION 
The veterinary medicine profession may be organized into two broad specialties: 
Livestock medicine; and Companion animal medicine. Dealing with livestock is easy 
compared to dealing with companion animals because livestock have clear economic value 
that allows their treatment costs to be judged against that value. For example, when the cost 
of a treatment of pig is determined to be greater than the value it can provide its owner, the 
decision to not treat is often easily made by the farmer. However, when the same pig is a 
pet, the decision becomes very complex. Now, the pet owner, not a farmer, is considering 
the emotional comfort the pet provides, and the pricelessness of the relationship.  
The emotional relationship between a pet and it owner can sometimes make the 
treatment of terminal diseases in the pet difficult. The complexity emerges when the desire 
for keeping the pet alive because of its emotional value to the pet owner causes the pet 
owner to have difficulty making decisions about the pet’s quality of life.  Often, pet owners 
believe that spending any amount of treatment is an indicator of their value for the pet. This 
can make the veterinarian’s work difficult when the quality of life effect of treatment is 
actually negative. It is a known challenge in the companion animal veterinary practice that 
conversations with pet owners about end of life questions for their pets are some of the 
most difficult.  
1.1 Research Problem and Research Question 
The focus of this research is to develop a means of easing the end of life 
conversations for pets between pet owner and the veterinarian.  It is premised on the 
assumption that the emotions and other cognitive issues related to the relationship with pets 
often obscure their owner’s ability to focus on the health and quality of life components of 
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the pet’s life during terminal illness.  Searching for a means to make the conversation 
between veterinarians and pet owners easier through the employment of some objective 
analysis is the problem motivating this research. An objective approach often overlooked in 
these conversation is an assessment of the pecuniary and non-pecuniary net benefits of the 
pet in the owner’s life during those terminal stages of an illness.  For example, when the pet 
is unable to provide the same joy for the owner, the quality of the pet’s life becomes a cost 
consideration that must be included in the conversation.  Unfortunately, without any tools 
for valuing these non-pecuniary aspects of the pet in the owner’s life, the decision becomes 
difficult and often intractable.  
The motivating research question is defined as follows: What economic tools may 
be used to help pet parents minimize their treatment costs and enhance the benefits they get 
from their pet, when a terminal problem develops.  This paper explores a benefit-cost 
model that veterinarians and clients may use to ensure terminally ill pets are offered the 
best quality of life with the minimum cost and maximum benefit to pet owners.   
Veterinarians strive to contribute by minimizing the use of opioids and address any 
contribution the veterinary industry might make towards the opioid epidemic.  
Pain is a major factor in helping owner decide when to allow a pet to give up on the 
struggles of life.  Conditions such as chronic arthritis are very painful. The pet may have 
significant difficulty moving or even sleeping when these conditions become very severe. 
Also, chronic heart and kidney disease and respiratory conditions, such as asthma, certainly 
can cause major distress during the final stages of a terminal illness. The pain often 
“cripples” the animal and prevents it from having a good quality of life. For example, it 
might have difficulty going about its business as it always has. This can be distressful for 
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the owner, but it is also very disconcerting for the animal.  Combining the pain 
management challenges and the declining quality of life issues is important for 
veterinarians and pet owners to develop the best solutions for managing terminally ill pets, 
including the consideration of euthanasia.  
1.2 Objectives  
The overall research objectives is to develop a decision support tool to enable an 
easier conversation between veterinarians and pet owners during conversations about 
terminal illness treatment protocols for the patter’s pets.  It seeks to provide a “metric” that 
allows for the subjective to become “objective” in these conversations and help both the pet 
owner and veterinarian provide the best care for a terminally ill pet, care that recognizes the 
pet’s quality of life as integral to the decision equation, even as it recognizes the owner’s 
psychological needs and responsibilities to the pet.  
The specific objectives are as follows: 
a. Describe the economics of pain management in companion animals.  
b. Simulate the pecuniary and non-pecuniary costs and benefits associated 
with treating a hypothetical terminally ill canine pet and the potential 
decision options a pet owner might make. 
c. Evaluate the potential effects of pet owners’ evaluation of pet comfort, 
owner’s separation anxiety and medical treatment costs on pet owner’s 
decision about euthanasia.  
1.3 Outline of Thesis 
The foregoing chapter has presented the background, research problem, research 
question and objectives framing this research. Chapter 2 presents a brief literature review of 
the opioid crisis in more detail, tracing its origin and the factors contributing to the crisis. It 
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also explores the real or perceived contribution of the veterinary industry to the human 
opioid crisis and the challenges that present to the profession. Chapter 2 also covers 
regulations being proposed and imposed, and possible problems that they present to 
veterinarians and veterinary clinics. It explores non-pharmaceutical and non-traditional 
pain management options available for veterinarians and assesses their effectiveness based 
on the literature assessments. It reviews the value of a pet to an owner, and how the value 
may change if separation anxiety factors and emotional costs change. Chapter 3 presents 
the data and conceptual models for assessing the economics of pain management using a 
hypothetical canine pet with terminal cancer as the reference for simulating the potential 
outcomes under alternative therapies. It also evaluates the potential effect of pet owner 
socio-economic characteristics on pain management options.  Chapter 4 presents the 
simulation results for the hypothetical canine pet with terminal cancer.  It assesses the 
alternative benefit-cost outcomes for the different therapies, recognizing the factors or 
separation anxiety and emotional costs on the model.  Chapter 5 develops a process that 
veterinarians might use with these results to engage their clients in conversations to 
facilitate the best humane decisions for pets and determining the best cost benefit ratio for 
pet owners. The conclusions and recommendations for future research are  in the final 
segment.
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CHAPTER II: PAIN MANAGEMENT IN VETERINARY MEDICINE 
The literature on pain and pain management in the veterinary industry is critically 
explored in this chapter. The chapter is organized in five sections. The first provides a 
review of pain among animals and how veterinarians have addressed this through time. It 
also explores the use of opioids by veterinarians and the associated costs of alternative 
therapies.  Section 2.2 presents a review of state and federal regulations guiding 
veterinarians’ use opioids and other therapies as well as potential regulatory actions being 
considered for veterinarians, including collecting information about their clients’ addiction 
and drug use profiles. The review explores veterinary industry’s responses to these 
proposals, arguing that their implementation would increase the cost profile of all clinics 
and practices, as well as increase the potential insurance costs facing veterinarians. Sections 
2.3 and 2.4 discusses guidelines for veterinary opioid use and why veterinarian should 
consider limiting opioid for pain management.   Section 2.5 reviews the processes used by 
veterinarians to develop veterinary treatment plans under alternative presentations, and 
evaluates how to deal with chronic pain under terminal disease conditions.  It discusses 
how to manage chronic or cancer pain in a veterinary setting.  Section 2.6 explores the 
literature on companion animals and the prevalence of diseases among companion animals.  
It then develops the “model” of a canine companion animal with a terminal disease 
situation, and discusses the decision choices within the context of treatment plan and 
related cost considerations. It also discusses the measurement challenges associated with 
non-pecuniary metrics, such as emotional attachment, and animal comfort and pain level. 
The final section 2.7 goes over the value of a pet over its life time. 
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2.1 Pain and Pain Management in Animals 
Most veterinarians do not want to see an animal in pain. Some veterinarians have 
learned in the past 10-15 years that the newer opioids seem to have the best pain control 
opportunities. Some pharmaceutical companies have been developing longer acting 
products such as fentanyl patches which could be applied before surgery and give the 
patient several days of post-operative pain reductions. Pharmaceutical companies find the 
human market for these products was much more lucrative than the veterinary market so 
most companies did not get veterinary classification. Some research indicates opioid 
analgesics may not be as well tolerated and metabolized by the animal patients, blood 
plasma concentrations are not as high in dogs as in people and show more patient variation. 
More pharmacy testing of opioids in animals is still needed (Benitez 2014).  For example, 
Tramadol is not considered effective at alleviating pain in canine patients, especially when 
used alone. Veterinarians can still use theses human drugs if 
 a. there was not an animal drug approved for this intended use  
 b. the animal drug did not come in the required concentration or dose needed  
 c. the veterinary product was not effective 
   These drugs must be used in the context of a client patient relationship. 
Veterinarians could then try a human extra label drug (such as an opioid that has not been 
approved for animals).  There are only two opioids specifically approved for use in 
animals, and only two are currently being marketed (buprenorphine for use in cats and 
Butorphanol@ for use in cats, dogs, and horses). Wildlife Laboratories, the maker of a 
potent analog of fentanyl called carfentanil (Wildnil@), voluntarily relinquished the 
approval for this product March 2018 (Federal Drug Administration 2018). The company 
probably wanted to avoid the possibility of diversion of the drug (roughly 10,000 times that 
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of heroin) (Illinois College of Veterinary Medicine - Ashley Mitek, McMichael, and 
Schlosser 2017) and limit its possibility of increasing the human opioid epidemic. In a valid 
veterinary-client-patient relationship the veterinarian makes the medical judgment on the 
health of an animal, and the need for medical treatment. In turn, the client (owner, 
caretaker, or employee) has agreed to follow veterinarian’s instructions. A general or 
preliminary diagnosis of the medical condition is obtained and availability for after care 
(emergency) is provided. Currently telemedicine is not considered a viable option for 
control drug dispensing. A relationship can only exist when you have recently seen and are 
personally acquainted with the keeping and care of the animal or animals. You must have 
recently examined the patient, and made "medically appropriate and timely visits" to the 
premises or them to a veterinary hospital (Federal Drug Administration 2017).  
 Opioids are among the most effective analgesics in medicine, and commonly used 
to treat terminally declining pets. They are used to manage acute pain in companion 
animals, either alone or in combination with other analgesics. The euphoric effect of 
narcotics (mainly mu agonists), dependency, and the adverse conditions of withdrawal in 
humans has led to the current epidemic of opioids in humans. We usually expect some of 
the same effects to be found in animals. Some pharmacokinetic studies indicate they may 
not work as well in animals as they seem to in human patients (Benitez 2014).   
 Medical staff were encouraged by experts and pharmacy representatives to manage 
pain with opioids in the 1990s and early 2000s without realizing the addictive properties of 
these drugs. According to the CDC web site an average of 130 human deaths a day are due 
to Opioids. It is alarming to see the number of these deaths in this country. Most of these 
are illegal drugs (heroin and synthetic opioids) that are sold on the streets, but some are 
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prescribed by well-meaning medical providers. The drug problem is very complex 
involving products such as cocaine, fentanyl, heroin, home derived synthetic drugs and 
medicinal opioids. Many people get good pain control initially and then seem to require 
higher doses with more side effects as time on the medication persists. All seem to be 
culminating in a human epidemic in this country, we will look at Veterinary Medicine to 
see if it is contributing to the problem. As human doctors are more reluctant to prescribe 
opioids, human addicts may consider veterinarians as a source of their opioids. 
Veterinarians as well as other health care professionals may feel pressure to prescribe them 
for people’s animals which could be subverted to a human with an addiction.  
           Veterinarians are trained on the best ways to control pain in animal patients, and this 
often includes the use of opioid medication.  Acute pain of surgery and often end of life 
care of chronically ill and debilitated animal patients usually involves a form of a narcotic 
pain medication. Many veterinarians felt at “arm’s length” from the opioid epidemic 
because the patients could not open a pill vial or randomly increase their doses of 
medication. Owners are required to refill and administer the medication, but subsequently 
serve as a possible source of misuse and diversion. Some owners allege to invent 
symptoms and exploit the older or injured animal in order to get opioid medication for 
human use. 
 According to the National Institutes of Drug Abuse 2019, the opioid epidemic 
began in the late 1990s largely as a result of the perception that “patients in pain should not 
be denied opiates” and that patients pain communities were exploited by the 
pharmaceutical industry in the aggressive marketing of opioid based products. The 
unrestricted doctor prescribing, misuse and widespread diversion has resulted in a marked 
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and continuing increase in substance abuse, diversion and lethal death toll. The United 
States is now seeing this epidemic have taken a frightening human death and economic toll 
(Muir, et al. 2018). 
2.2 Review of State and Federal Regulations Guiding Veterinary Use of Opioids 
 Opioid prescriptions in the United States have increased from 76 million in 1991 to 
207 million in 2013 (Schuchat, Houry and Guy 2017). The human medical community had 
a significant increase of use in the 1990s. Once used primarily for the treatment of acute 
pain or pain due to cancer, physicians began using opioids for anyone experiencing chronic 
pain. This has been accompanied by rising rates of accidental addiction and many 
overdoses leading to death.  Some states are enacting new laws or strengthening existing 
ones in an effort to limit access to opioid medication. According to the American 
Veterinary Medical Association, 17 states and Washington DC have regulations requiring 
veterinarians to report, though Prescription Monitoring Programs, when they dispense 
opioids and other controlled substances to patients (Alaska, Arkansas, California, 
Colorado, Connecticut, Illinois, Indiana, Maine, Michigan, New Hampshire, New York, 
North Dakota, Oklahoma, South Carolina, Vermont, Washington, and West Virginia).  
However, some of these mandates are on hold while legislatures decide how to implement 
this regulation. It is important for all practitioners to check with their state veterinary 
medical and pharmacy boards to ensure compliance with current laws and regulations. If a 
controlled substance is ever stolen or missing from a veterinary hospital inventory it needs 
to be reported to the Drug Enforcement Administration and local police department 
(AVMA 2018). 
 In a recent town hall meeting with the Colorado PDMP (Prescription Drug 
Monitoring Program) Veterinary Advisory group it was stressed that all practitioners 
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licensed to practice in Colorado should register and have access to check patient and owner 
narcotics use on any client they feel may be at risk for diversion or misuse before an opioid 
prescription is used (Adams, Meola and Newman 2019). 
Illinois law was to have required all opioid prescribing veterinarian to be registered for 
client access by January 1, 2018, but has been slow at implementing the PMP information 
and confidentiality information. On October 13, 2019 the Illinois Legislature exempted 
veterinarians from the PDMP requirements, and requires three hours of controlled 
substances training on “Safe Opioid Prescribing”.  
2.3 Veterinary Guidelines to avoid Veterinary Clients Addiction Issues 
 Veterinarians try to identify, deter and report customers shopping for controlled 
drugs or trying to divert them for human use:  
2.3.1 Companion Animal Facilities  
In companion animal facilities, things to watch for include:    
• New clients bringing in seriously injured animals with strange or vague histories  
(These cases should be hospitalized and treated not just sent home on opioid medication 
  In some cases people have been known to harm a pet to get narcotic medication!) 
• Old, incomplete, or non-verifiable veterinary care records  
• Describing clinical signs that are inconsistent with findings on examination of the patient  
• Describing clinical signs that require specific medications (seizures or chronic pain) 
• Requesting medications by name (e.g., Tramadol or Xanax) for the pet’s issues 
• Refusing medications as prescribed and suggesting alternatives in the opioid class 
• Requesting early refills of medication, or large amount for long vacations 
• Claiming medications were lost, stolen or not given to them at check out (consider 
surveillance video at checkout area) 
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• Requesting refills, while missing appointments (client too busy working to bring pet in, 
but he needs more meds now) 
• Uncooperative and aggressive owner behavior when discussing pain medication 
   Make sure to document on patient chart, dosage administered, treatment duration 
  2.3.2 Large Animal for Food Production 
The concern is large animal veterinarians less commonly prescribe opioids but if used 
dosages could be much higher than in small animal patients. (follow general guidelines) 
 Carefully diagnose and evaluate the condition for which you are prescribing drug. 
 Make sure clients can maintain the identity of the treated animals or animals 
 Establish adequate withdrawal periods so no illegal drug residue in treated animal 
reaches the food chain. 
The vast majority of veterinarians whether they work in a small rural veterinary clinics or a 
large specialty clinic with thousands of clients all went into veterinary medicine to help 
animals and take the Hippocratic oath seriously, to provide the best quality medicine that 
the client can afford. Opioids have always been an option for those patients that are in 
severe pain. The altruistic value to the client and practitioner would be similar, (for all 
practice types), however in larger practices when clients do not see the same doctor each 
visit, the risk of opioid abuse may increase. It is best for doctors and staff to have uniform 
policies in place for dealing with controlled drugs and treat all clients with respect but 
caution in this area.  When the animal dies or is euthanized, proper disposal of remaining 
pain medication should be encouraged. 
2.4 Treatment Plan  
 Veterinarians should try to follow recommended guidelines for dosage (some listed 
Table 2.1). For example, cats who are experiencing geriatric arthritis often show improved 
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mobility and corresponding improvements in quality of life at 2 mg/kg of Tramadol dosed 
twice daily.  Side effects often increase at 4 mg/kg twice daily (Alonso, et al. 2018). Many 
veterinary reference formularies have a limited dosages of pain medication, because most 
are not approved for animals. It is important for veterinarians to have a guideline for doses 
and have alternatives to consider when addressing chronic pain in patients.    
 Although the Federal Drug Administration and Drug Enforcement Administration 
do not intend to directly limit availability of opioid drugs to the veterinary market, there 
may be some interruptions and restrictions of full mu agonists including morphine, 
hydromorphone and fentanyl. Some of the pharmacy production facilities in Puerto Rico 
were damaged in Hurricane Maria and are not fully functional yet. The demand for many 
of these drugs is expected to decrease by 20% per year. Pfizer does not anticipate resuming 
sales of some veterinary injectable opioids, and the federal government has directed a 
decrease in production of certain highly abusive Schedule II drugs.  The trend to no longer 
make multi-vial bottles, will greatly decrease use in veterinary medicine as single use/ 
preservative free human doses are much more expensive (Pfizer 2019). Veterinarians have 
a lot of variation on size of pets treated and single dose and discard vials are much more 
expensive to inventory and use in veterinary medicine. 
2.5 Canine Cancer Pain Management 
 Pain medications are commonly used to treat animals undergoing cancer 
treatments. Not all tumors are painful and not all pets with arthritis need to take an opioid 
or cannabis products to control their pain. The flow chart presented in Figure 2.1 may help 
in assessing the decision to adopt certain treatments based on the pain experienced by the 
animal.  It suggests that all aspects of pain be considered including any relevant side effect 
of the treatment regime. Stronger drugs or combinations of drugs are to be considered only 
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when the pain level becomes unbearable. And beyond that, euthanasia must be considered 
for humane reasons. 
Figure 2.1: Evaluating Animals With Pain 
 
 
 
 Source: Adapted from (Lascelles 2015, 250) 
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 Pain may be organized into a number of classes (Atkinson Smith and Hambleton 
2014, 76):  
1. Neuropathic pain, which humans feel, is poorly controlled by opioids, is 
typically described as shooting pain, burning, radiating, tingling, and 
numbness.  
2. Somatic pain is typically a throbbing, dull, achy in addition to being 
localized in nature, and pet is usually requiring multi drug treatment 
approach.  
3. Visceral pain is usually post-surgery of the abdomen or thoracic areas. This 
type of pain may also be present as a secondary result of liver cancer 
metastases. Visceral pain will usually require opioids and multimodal 
therapy as well to control all the pain (Atkinson Smith and Hambleton 
2014).  
Pain is difficult to communicate in humans and much more difficult in animals.  
Various pain scales have been developed to help people in pain discuss or communicate 
their pain to caregivers.  Pain Doctor (https://paindoctor.com/pain-scales/), a website 
organized by a group of pain management professionals, including physicians and 
chiropractors, delimits no less than 15 of these pain description scales and charts.  For 
example, there is the Wong-Baker FACES, the Global Pain Scale, and the McGill Pain 
Scale.  The Color Scale of Pain describes the severity of pain being experienced on the 
basis of color and a number, ranging from 0 to 10 and blue to red (Figure 2.2).  Using this 
Color Scale of Pain, humans are asked how much pain they are experiencing based and a 
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response of 0 implies no pain.  Levels 1 and 2 present hardly noticeable pain and awareness 
of pain only when attention is drawn to it.  The color changes from blue to increasing 
darker shades of green. By the time the pain is rated a 7 or higher, the color changes to 
deep crimson from dark orange.  At these levels, the human patient would describe their 
pain as unmanageable, implying they are in pain all the time, and the pain keeps them from 
doing most activities, to they are unable to move (10), they are laying down all the time, 
unable to move because of the pain.  In one commentary, 10 on the color scale was 
described as willing to choose death if pain cannot be reduced.  But pets cannot provide 
this feedback.  
Figure 2.2: The Color Scale of Pain 
 
Source: https://paindoctor.com/pain-scales/ (Pain Doctor 2018). 
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 Colorado State University Veterinary Teaching Hospital (CSUVTH) has developed 
the Canine Acute Pain Scale to help describe the pain level in dogs.  Like the human scale 
above, it uses colors.  However, it includes poses, numbers and description of 
psychological and behavioral state. It also uses the dog’s response to palpation and the 
body tension it exhibits (Figure 2.3). For example, pain score of 0 on the CSUVTH  is 
described as comfortable when resting, looking happy and content and not bothering their 
wound or surgery site. Body tension is zero and the surgery site is non-tender to palpation. 
By scale level 2, the dog visibly uncomfortable when resting and may whimper and does 
not respond when beckoned. The dog expresses no interest in people. A score of 4 on the 
CSUVTH pain scale would have the dog constantly groaning or screaming when 
unattended and may bite or chew at pain site.  It is difficult to distract the dog from its pain 
(Colorado State University Veterinary Teaching Hospital 2016).  
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Figure 2.3: Colorado State University Veterinary Teaching Hospital Canine Acute 
Pain Scale 
 
(Colorado State University Veterinary Teaching Hospital 2016) 
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The pain management chart (Figure 2.1 above) showed that opioids are used for 
non-responsive pain. Short-term pain medicine is used after surgery or illness but rarely is 
used longer than 3 to 14 days for most pets. Owners would often assist with physical 
therapy, range of motion exercises and encourage pets to return to normal function as soon 
as possible, rather than relying on pain medication in non-chronic conditions.  Table 2.1 
describes the recommended dosage for pain medicines in canines and the issues that need 
to be assessed when using them.   
Table 2.1: Dosage of Canine Medication 
Drug Dose for Dogs Comments 
Paracetamol–Tylenol 
(acetaminophen)@ 
10-15 mg/kg PO 
q12 hours. 
Associated with fewer GI side effects than regular 
NSAIDs. Monitor liver and kidney values. Toxicity 
has not been evaluated clinically in dogs. Could be 
combined with regular NSAIDs in severe cancer pain, 
but this combination has not been evaluated for 
toxicity. 
Paracetamol 
(acetaminophen) 
10-15 mg/kg of 
acetaminophen 
Sedation can be seen as a side effect with doses at or 
above 2 mg/kg of codeine. 
+ codeine (30 or 60 
mg) 
Amantadine- 
Symmetrel@ 
4.0-5.0 mg/kg PO 
q24 hours. 
Used to treat Influenza A, can cause loose stools and 
excess GI gas can be seen for a few days. Should not 
be combined with drugs such as selegiline or sertraline  
possible drug interactions. Should not be used in 
seizure patients or patients in heart failure. 
Amitriptyline-Elavil@ 0.5-2.0 mg/kg PO 
q24 hours 
Antidepressant, has not been evaluated for clinical 
toxicity in the dog. Should be used cautiously in 
combination with tramadol. 
Butorphanol-
Torbutol@, 
Torbugesic@ 
0.2-0.5 mg/kg PO 
up to q8 hours 
May produce sedation at higher doses. Not a very 
predictable analgesic, and best when used in 
combination with other analgesics. 
Codeine 0.5-2.0 mg/kg PO 
q8-12 hours 
Sedation can be seen at higher doses. Like all oral 
opioids, it is subject to liver metabolism before 
reaching circulation, limiting some of its analgesic 
effect. 
Fentanyl, transdermal 2-5 mcg/kg/hr Can be very useful in the short-term control of pain. 
For long-term therapy, usefulness is limited due to 
need to change the patch every 4 to 7 days. 
Gabapentin 3-10 mg/kg PO q6-
12 hours 
Has not been evaluated in dogs as an analgesic. The 
most likely side effect is sedation. 
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Drug Dose for Dogs Comments 
Glucosamine,and 
chondroitin sulfate 
13-15 mg/kg 
chondroitin sulfate 
PO q24 hours 
Can be useful in a variety of chronic pains due to its 
mild anti-inflammatory and analgesic effects. 
Morphine, liquid 0.2-0.5 mg/kg PO q 
6-8 hours 
Can be useful for dosing smaller dogs. Sedation and 
particularly constipation are side effects that are seen 
as the dose is increased. Like all oral opioids, it is 
metabolized by liver early. 
Morphine, sustained 
release 
0.5-3.0 mg/kg PO q 
8-12 hours 
Doses higher than 0.5-1.0 mg/kg are often associated 
with unacceptable constipation according to owners, 
so suggest using 0.5 mg/kg several times a day. With 
oral opioids bioavailability may be limited by liver 
metabolism. 
Pamidronate 1-1.5 mg/kg slowly 
IV diluted in 4 
mL/kg normal 
saline, administered 
over 2 hours; repeat
Inhibits osteoclast activity and thus only provides 
analgesia in cases suffering from a primary or 
metastatic bone tumor that is causing osteolysis. Effect 
may be delayed days-weeks. 
 every 4-6 weeks  
Prednisolone 0.25-1 mg/kg PO 
q12-24 hours; taper 
to q48 hours if 
possible after 14 
days 
Do NOT use concurrently with NSAIDs. Can be 
particularly useful in providing analgesia when there is 
a significant inflammatory component associated with 
the tumor and for CNS or nerve tumors. 
Tramadol 4-5 mg/kg PO q6-
12 hours Orally 
 This drug has not been evaluated for efficacy or 
toxicity in dogs. Currently felt to have very limited 
efficacy in dogs 
 
The basic doses primarily come from Oncology of Small Animals, the author’s 
experience and the experience of others working in small animal medicine (Lascelles 2015, 
251).  
None of these drugs have been evaluated for efficacy in the treatment of chronic 
pain or cancer pain.  
None of these drugs in table 1 or appendix B are approved or licensed for use in 
chronic or cancer pain. The NSAIDs have not been included in this table.  
Normally NSAIDs should be used as a first line of pain relief, if it is clinically 
appropriate and should be used at their approved dose on bottle, whenever possible. 
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 There is currently no information (evaluations or efficacy) on the long-term use of 
oral opioids for chronic pain or cancer in cats. 
 None of these drugs are approved or licensed for use in chronic or cancer pain. 
Some drugs are approved for inflammatory or painful conditions in the cat in 
certain countries, and doses for the control of chronic pain or cancer pain are 
extrapolated from these (Lascelles 2015, 252-253). 
 Most veterinarian will utilize their training and knowledge of pharmacology to only 
stock the best products and will write a prescription to an outside pharmacy for any 
that would not be cost effective to inventory. It costs a lot to inventory drugs that 
are rarely used and often outdate before another animal will use that medication or 
dosage of medication.  When patients are in a terminal decline, they may not 
require refills before death or euthanasia. 
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2.6 Prevalence of Different Types of Companion Animal Diseases 
 A common trend noted in veterinary practice in the past 10 years is obesity in cats 
and dogs.  As pets become more intimate parts of the family and daily life, many humans 
spoil their pets with higher calorie food, treats and less exercise. 
 Obesity changes are often subtle, and owners do not get worried until a friend or 
veterinarian explains that a couple pound increase on a 10-pound pet is equivalent to a 10 
to 20% increase in weight.  As with humans, it takes several months of concentrated effort 
to get a weight loss program to work, and rarely is easy. 
 Chronic kidney disease is more common in cats; however, it can affect dogs as 
well. Geriatric animals are more at risk than younger pets. Normally about half of the pets 
with early kidney disease are asymptomatic (i.e. owners do not know they have a problem). 
Animals with kidney disease, critical processes become impaired and affect the body in 
many ways such as urination problems, nausea or high blood pressure, depending on the 
nature of the disease. Dogs and cats may be born with unhealthy kidneys, or they may 
develop kidney problems as they age.  
 Chronic kidney disease is usually progressive and permanent, so early diagnosis is 
critical. Veterinarians should do blood and urine testing to diagnose problems early. Most 
animals are not showing symptoms initially, but early detection and treatment can increase 
longevity by several years. Dogs and cats that are diagnosed early can be placed on special 
diets and receive other veterinary-prescribed treatments. The following charts depict the 
most common veterinary diseases seen in 2011 in Banfield Hospitals and are similar to 
conditions observed in practice in Illinois and Florida (Banfield Veteriary 2012). 
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Figure 2.4 Geriatric Canine Disease Prevalence 
 
Figure 2.5 Geriatric Feline Disease Prevalence 
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2.7 Pet Value to Pet Owners 
 Most Americans feel the pet is a member of the family and the animal-human bond 
increases over time. Many clients cannot go on vacation or attend family gatherings unless 
the pets are able to attend also.  In a recent discussion at an agribusiness social, most people 
indicated that a pet is more caring and compassionate than a spouse. From the anecdotal 
information obtained from discussions with friends (most of whom have pets at home) an 
estimated value of a pet to its owner is about $1000.  The discussion in Chapter 4 will use 
the benefit-cost ratio to help guide owners and veterinarian to determine when the topic of 
humane euthanasia should be entering into the discussion. Understanding these dialogs are 
very challenging at times, and the veterinarians will be guided by the family’s feedback of 
the patient’s terminal care. 
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 CHAPTER III – DATA AND CONCEPTUAL MODEL FOR TREATING 
TERMINAL DISEASE IN VETERINARY MEDICINE  
 Beyond a certain point of the progression of a terminal illness, such as cancer, the 
treatment focus moves from curing to alleviating pain and ensuring patient comfort.  This 
chapter presents a conceptual model for assessing the potential economic implications of 
managing pain in pets during a terminal decline. Companion animals are the primary focus 
because food animals and livestock are often driven in a more straight-forward economic 
way.  If treatment cost exceeds the market value of the animal, owners do not treat.  
However, with companion animals, the decision is often complicated by emotional 
attachment.  For some pet owners, the animal takes on a family member position, making 
them consider treatment for any terminal disease at the same par as treatment for similar 
diseases for their human children or relatives.  This section shows how the conversations 
about treatment decisions might be influenced by the economics of such decisions.  
 The chapter is divided into three main sections.  The first section presents the 
conceptual model for treating terminally-ill companion animals. Section 3.2 describes the 
conceptual model developed to explore the decision making process under alternative 
scenarios. It also describes the different scenarios that are considered.  The final section 
presents the data and their sources employed in the analyses.   
3.1 Treatment Models 
In this research, we have represented the final six-week treatment profile for a 
terminally-ill canine. The treatment profile reflects the treatment plan used for a 
hypothetical 80-pound canine with terminal cancer beginning six weeks before its demise. 
Because both the pet owner and the veterinarian know that the pet cannot be treated at this 
stage of its disease progression, the focus of the treatment profile is to ensure maximum pet 
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comfort during this time and make the necessary economic and emotional decisions related 
to care.  
Treatment plans in terminally ill cancer pets focus on pain management aimed at 
increasing pet comfort after chemotherapy. This is because patients in this stage of their 
disease are unlikely to get better. However, some pet owners are unwilling to accept that 
finality and the veterinarian has to manage their expectations by focusing on the comfort of 
the pet, which is the patient.  Veterinarians would use Rimadyl@ or similar nonsteroidal 
anti-inflammatory drug at the start of this and adjust the pain management regime usually 
with more powerful pain management therapies over time. Additionally, medical 
evaluations by the veterinarian and blood work to monitor internal organs, electrolytes and 
complete blood count are routinely done, at least on a weekly basis, to make sure the 
chemotherapy does not need to be adjusted.   
The following weeks Cannabinoids (CBD) and Gabapentin may be added to adjust 
for increasing pain noticed by owner (table 3.1).  Based on the pain situation, the care team 
and the owner might elect to try some narcotic by the end of Week T-3, where T is the end 
date.  By then most of these cases are not likely to get better and pet comfort requires more 
aggressive pain management. By Week T-5, signs of pet discomfort become more visible, 
manifested in howling and crying, whining and painful looks. At this point, an opioid, such 
as Fentanyl patches, could be applied to manage the pain, given that it is more potent than 
Tramadol.  Conversations with pet owners at this time explains that this medical care will 
not make the pet better, but only manage its pain. The administration of pain management 
medication in increasing dosage will continue until the pet dies naturally or the pet owner 
elects euthanasia.  
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3.2 Conceptual Treatment Models 
Owners faced with a terminally ill pet must evaluate how much they spend on the 
treatment of the pet (pecuniary expenses). That assessment, unlike that of production 
livestock, is complicated by how attached pet owners are to their pets. It is also influenced 
by the emotional cost (non-pecuniary cost) of the illness on the pet owner. A very sick 
animal could extract a very high emotional cost on its owner by constraining the owner’s 
movement and disrupting their normal routines. For example, a pet that is unable to walk 
due to a terminal illness may have to be carried outside for its bodily functions, restricting 
its owner’s ability to leave her for a long period.  If the owner has to leave, then they have 
to hire the services of someone who can help the pet with these needs it is unable to 
undertake on its own. The assessment also includes the medical costs associated with the 
treatment.  These are the medications and professional services that are provided to care for 
the animal. The final consideration in the assessment is the value of the pet to the pet 
owner.  
Let us explore the conceptual relationships among these variables (value of pet, 
separation anxiety, emotional cost factor and benefit cost ratio) we are using to assess the 
treatment decision about a terminally ill companion animal.  Let the value of the animal to 
the pet owner be V.  Assuming that this value is independent of the pet’s disease but 
dependent on how long the pet has been with the owner. The relationship between V and 
duration of the pet-owner relationship is positive and increasing but at a decreasing rate 
after some time. This implies that beyond a certain period, the value of the pet is constant 
to the pet owner most of its mature adult life. It is also assumed that this value towards the 
end of the pet’s life can change, depending on the pet owner’s disposition and perceived 
bond with the pet.      
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The potential change in the value of the pet to the pet owner is dependent on the 
separation anxiety the pet owner experiences with the imminent death of the pet.  If the pet 
owner does not experience any separation anxiety, then the value remains unchanged. If the 
pet owner does experience some separation anxiety towards the end of the pet’s life, then 
that will increase the perceived value of the pet to the pet owner as the inevitable date gets 
closer. The separation anxiety model, therefore is a function of time and its impact is 
transferred through the pet owner’s value for the pet.  
Emotional cost of the pet’s illness is modeled as a rate of increase in the cost of 
pet’s care directly attributable to changes in the pet owner’s life. It could be the cost of 
missing work, sleepless nights, or new nursing skills to take care of a pet that is 
increasingly unable to take care of itself. In this conceptual development, the model simply 
shows an increase in the medical cost of care over time. Medical cost of care is the 
cumulative cost of drugs, diagnostics and professional fees related to the treatment of the 
pet. The model is assumed to focus on the last six weeks of the pet’s life. This is the period 
where deterioration in the quality of life of the sick pet can be rapid and also visible. 
Conceptually, the total cost of care at any point in time, C, is defined as follows: 
 ( )C MC EC   (3.1) 
  
When MC is the medical cost and EC is the emotional cost.  Emotional cost has been 
modeled as a growth function of medical treatment cost and time. The emotional cost 
factor, e, is the adverse effect of care on the owner; it is assumed dependent on the medical 
care cost.  These adverse effects include the increased time for care giving and loss of time 
available for other activities. Specifically, the emotional cost is defined as: 
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 tt tEC MC e  (3.2) 
Value of the pet, in this research, is defined as an integer that is influenced by the 
separation anxiety factor at any point in time.  Therefore, it is modelled as follows: 
 1t t tV s V   (3.3) 
Where “s” is the separation anxiety factor and “t” is time.  The relationship between “s” 
and “t” is dependent on value in the prior time period. The separation anxiety factor could 
go up or down each week, but would correspond to the value of pet now divided by value 
of pet in prior time period (here one-week interval). An owner with a lower separation 
anxiety level who understands that either they cannot extend the pet’s quality life or cannot 
afford the time and monetary needs beyond a certain point of their pet value estimate would 
be more likely to consider euthanasia.  
We use the benefit-cost decision framework to facilitate the decision making by the 
pet owner on when to stop treatment.  The decision guide for the BCR (benefit-cost ratio) 
framework is as follows: 
 
1:
1:
1:
t
t
Continue treatment
VBCR Indecision
C
Discontinue treatment
 
 (3.4) 
The decision point for consideration of euthanasia is defined as when the benefit cost ratio 
is less than unity. 
3.3 Data Sources 
 The foregoing analysis is based on the treatment of a terminally ill canine, who 
started treatment at about 80 pounds.  It focuses on the last six weeks of treatment, 
assuming the decision to continue treatment will be evaluated weekly using the above 
model. The example cited uses routine medication and hospital costs were obtained from 
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Novak Brainard Veterinary Clinic in Illinois and the retail cash price of medication (in US 
dollars) from a large national pharmacy. The treatment regime is assumed to begin after the 
pet has undergone chemotherapy for cancer treatment and remission has been ruled out.  
The owner has been left with a terminally declining pet with an expected 6 weeks 
prognosis.  The sample treatment model presented in Section 3.1 is reflected to show 
possible medications and cost presented in Table 3.1.  We have excluded the specific 
dosage applied to protect potential use of this information by non-professionals in the 
treatment of a terminally ill canine.  
 Table 3.1 shows that at the beginning of treatment (Week 0), we recommended 
treatment with only a non-steroidal anti-inflammatory (NSAID) medication. We also 
assume diagnostic blood tests are conducted and the veterinary services are provided. The 
total cost for medical services and medication in this initial week is estimated at $122.81.  
The table shows the inclusion of Gabapentin and CBD in Week 1 and 2. An oral opioid 
such as Tramadol is added in week 3 and 4. A description of treatment plan is in Section 
3.1 above. 
Table 3.1: Weekly Medical Treatment Cost Assumptions 
Week Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Total 
NSAID  $17.81   $17.81  $17.81  $17.81  $17.81  $17.81  $15.26   $122.11 
Gabapentin   $78.79  $78.79  $78.79  $78.79  $78.79  $67.53   $461.48 
CBD   $24.99  $24.99  $24.99  $24.99  $24.99  $21.42   $146.37 
Tramadol     $71.12  $71.12    $142.24 
Fentanyl       $72.00  $72.00   $144.00 
Blood Test  $85.00   $85.00  $85.00  $85.00  $85.00  $85.00   $510.00 
Vet 
services  $20.00   $20.00  $20.00  $20.00  $20.00  $20.00  $20.00   $140.00 
Euthanasia        $100.00   $100.00 
Total 
Medical 
Cost 
$122.81  $226.59 $226.59 $297.71 $297.71 $298.59 $296.22  $1,766.21 
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 In Table 3.2, we show the emotional cost factor and the separation anxiety factor 
parameters for the scenarios considered in this research.  In total, we consider six scenarios, 
including the Base Scenario.  The separation anxiety factor under the Base Scenario was 0, 
suggesting that we are considering a situation where the pet owner does not exhibit any 
separation anxiety about the imminent demise of the pet.  Based on the Value equation, this 
results in a constant pet value over time.  As the separation anxiety increases, the ability of 
the owner to part with the pet becomes more difficult.  Thus, under Scenario 1, the 
separation anxiety factor is assumed at 0.1, leading to a base value of $1,000 being $1,772 
by terminal time period (table 3.2 and figure 3.2). Similarly, the emotional cost factor in the 
Base Scenario is assumed to be 0.15, because sick pets always disrupt the lifestyles of 
caring pet owners.  They either incur the cost of these changes directly through loss of time 
or they do so indirectly by paying someone to undertake their increased pet care duties.  
Table 3.2: Scenarios and their Alternative Parameters 
Scenarios Separation Anxiety Factor Emotional Cost Factor 
Base Scenario 0 0.15 
Scenario 1 0.1 0.3 
Scenario 2 0.2 0.6 
Scenario 3 0.3 0.9 
Scenario 4 0.4 1.2 
Scenario 5 0.5 1.5 
 
The trend in the emotional cost and medical treatment costs for the last six weeks plus the 
initial week for the Base Scenario is presented in Figure 3.1. The figure shows that 
emotional cost factor of 0.15, the emotional cost exceeds the medical treatment cost in 
Week 5, when all other things are held constant.  
 Figure 3.2 illustrates the trend in value of the pet to the pet owner under the Base 
Scenario and Scenario 1 parameters of separation anxiety. From Equation 3.2, the 
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implication of the separation anxiety parameter is that the value increases linearly at 10% 
per week in the terminal stages of the pet’s life. This is explained by the fact that the 
recognition that they would lose their pet in the near future fosters a desire to hold onto the 
pet more dearly by inflating its value. The other scenario is a pet owner who does not 
exhibit any separation anxiety, i.e., the separation anxiety factor is zero. 
 
Figure 3.1: Emotional and Medical Treat Cost Data Used in the Analysis with 
Emotional Cost Factor = 0.15 
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Figure 3.2: Pet Value to Pet Owner Under Alternative Assumptions about Separation 
Anxiety Factor (s) 
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CHAPTER IV:  SIMULATION ANALYSIS AND RESULTS  
 In this chapter, the results of our models are discussed and the implication of the 
analyses and how the analytical tool we used in this research may be used by veterinarians 
to help their clients in their decisions about terminally ill pets. The first section of the 
chapter provides a recap of the scenario characteristics. The second section presents the 
Base Scenario results, positioning them as a reference point from which the rest of the 
analyses take off.  Section 4.3 presents the results of the simulation of the separation 
anxiety factor while Section 4.4 presents those of the emotional cost factor. Section 4.5 
organizes the results as a way of engaging pet owners who have high separation anxiety, 
and would like to treat their pets “forever”, to have humane conversations about their 
choices.  
4.1 Pain, Humane Treatment and Love  
 Treating a pet with chronic pain can be expensive and emotional. In other medical 
conditions of terminal pet decline, veterinarians’ will focus on other quality of life factors 
in addition to pain.  Recall that this research is about managing the pain of an 80-pound 
canine with terminal cancer.  The treatment in Week T-6 = 0, when it is assumed the dog 
has completed a section of chemotherapy for the cancer. T is the terminal stage, defined 
here to mean six weeks after the terminal chemotherapy treatment.   
 Chemotherapy always induces significant pain that can cause massive discomfort 
for the dog, which can disturb the pet owner immensely. This interaction between the dog’s 
pain and the pet owner’s discomfort connects the latter’s decisions and options to their own 
utility function. In other words, the choices pet owners make for their pets may not be 
altruistic since they are, through those actions, dealing with their own utility.  The pet 
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owner recognizes the deteriorating state of the pet and the increasing difficulty of managing 
the pain with increasing dosage of more potent medications. The pet owner begins to 
balance their love for their animals and the emotional torment of its demise on them, the 
pet owner, with the humane treatment of the animal. Euthanasia becomes an option, but 
when? This is the decision support tool that this research developed. The decision point for 
considering euthanasia is defined as when the benefit-cost ratio is less than unity. 
4.2 Base Scenario Analysis 
 It is assumed that separation anxiety is 0 and emotional cost factor is 0.15 under the 
Base Scenario.  Based on the medical care cost presented in Table 3.1, total medical costs 
over the terminal six weeks is $1,766.21 while emotional cost would be expected to be 
double that.  Thus, the emotional cost (sleepless night, missed work, nursing duties if pet is 
home etc.) associated with the dog reaching Pain Level 4 on the CSUVTH (Colorado State 
University Veterinary Teaching Hospital) scale is higher than cash expenses on medication 
and veterinary services. Thus, when not recognized, the cost of treating the pet in these last 
days is underestimated. Since the Base Scenario does not assume changes in separation 
anxiety, the value of the dog to its owner does not change. This leads to a benefit-cost ratio 
profile that decreases from 4.1 in Week 0 to 0.2 in Week 6. The benefit-cost ratio is 0.8 in 
Week 2, suggesting that the pet owner may euthanize the dog in that week to present the 
most economical decision in terms of out of pocket expenses on treatment and emotional 
cost of care experienced by the pet owner. Since that emotional care of cost is connected to 
the pain level of the dog, this decision also becomes a humane choice. The foregoing is 
summarized in Figure 4.1.  It is observed from this figure that emotional cost is a 
significantly and increasing share of total cost of care for the terminally-ill pet.  
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Figure 4.1: Value of Pet, Medical and Emotional Cost and Benefit-Cost Ratio in the 
Last Six Weeks of Life 
 
 
4.3 Separation Anxiety Scenarios 
 The separation anxiety scenarios assumed separation anxiety factor increasing from 
0 in the Base Scenario to 0.5 in Scenario 5, while holding all other parameters constant.  
The trends in value for the different scenarios are presented in Figure 4.2.  For example, 
when separation anxiety factor is 0.2 (Scenario 2), the terminal value of the pet in week 6 is 
$2,985.98. This compares to the terminal value of the pet under Scenario 5 (s = 0.5) of 
$11,390. The high value the pet owner places on the pet as she contemplates the separation 
from the pet through the pet’s demise distorts the relative expenditure on treatment and pet 
comfort. Indeed, this high value would suggest a “selfishness” on the pet owner’s part, 
where their pain of losing the pet is placed ahead of the humane treatment of the pet.  
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Figure 4.2: Pet Value Under Alternative Separation Anxiety Scenarios 
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treat with higher doses of more potent medications, e.g., opioids, even when the 
contribution to comfort is minimal or nonexistent.  
Table 4.1: Benefit-Cost Ratio Results Under Alternative Separation Anxiety Factors 
Week Base Scenario 
1 
Scenario 
2 
Scenario 
3 
Scenario 
4 
Scenario 
5 
Week 0  4.07  4.07  4.07  4.07   4.07   4.07 
Week 1  1.36  1.50  1.64  1.77   1.91   2.05 
Week 2  0.82  0.99  1.18  1.39   1.61   1.84 
Week 3  0.54  0.72  0.93  1.18   1.48   1.81 
Week 4  0.40  0.59  0.83  1.14   1.54   2.02 
Week 5  0.32  0.51  0.79  1.18   1.71   2.42 
Week 6  0.26  0.47  0.79  1.28   1.99   3.01
 
4.4 Emotional Cost Factor Scenarios  
  Emotional cost factor is assumed to increase by 0.15 in each Scenario, from 
0.15 under the Base Scenario to 1.5 under Scenario 5.  The effect of these changes on total 
cost is presented in the trends in total cost (medical care cost and emotional cost) in Figure 
4.3. It shows that the terminal total cost (medical and emotional) is in excess of $120,000 
because of the perceived emotional costs the pet’s sickness and pain imposes on the pet 
owner. These parameters were chosen to show the range of the decision support tool, 
allowing the veterinarian and the pet owner to explore alternative parameters that are 
realistic and relevant to the pet owner.  
  The effect of these emotional cost factors on the feasibility of euthanasia is 
presented in Table 4.2. Despite the seemingly outrageous assumptions about the emotional 
cost factor, the table shows that euthanasia is feasible only in Week 1 under Scenario 5 and 
not feasible until Week 2 under the remaining scenarios.  For example, the benefit-cost 
ratio was estimated at 0.73 under Scenario 1, 0.61 under Scenario 2, 0.51 under Scenario 3 
and 0.44 under Scenario 4  in Week 2, the same as the Base Scenario.   Scenario 2, 
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Scenario 3 and Scenario 4. Scenario 1 is the same as the Base Scenario, when euthanasia is 
feasible only in Week 4.  
Figure 4.3: Total Cost Trends under Alternative Emotional Cost Factor Assumptions 
 
Table 4.2: Benefit-Cost Ratio Under Alternative Emotional Cost Factor Assumptions 
Week Base Scenario 
1 
Scenario 
2 
Scenario 
3 
Scenario 
4 
Scenario 
5 
Week 0  4.07  4.07  4.07  4.07   4.07   4.07 
Week 1  1.36  1.30  1.20  1.11   1.03   0.96 
Week 2  0.79  0.73  0.61  0.51   0.44   0.37 
Week 3  0.50  0.43  0.32  0.23   0.17   0.13 
Week 4  0.35  0.29  0.18  0.12   0.08   0.05 
Week 5  0.27  0.20  0.11  0.06   0.03   0.02 
Week 6  0.21  0.15  0.07  0.03   0.02   0.01 
 
What if the separation anxiety factor is assumed to be 0.2 in these scenarios? The results 
show that euthanasia becomes feasible in Week 2.  Thus, the separation anxiety factor 
tempers the effect of emotional cost factor but not too much, changing as it were, the 
 $-
 $20,000
 $40,000
 $60,000
 $80,000
 $100,000
 $120,000
 $140,000
Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
To
tal
 Co
st
Time
Base Scenario 1 Scenario 2
Scenario 3 Scenario 4 Scenario 5
39 
 
results only in under Scenario 5, from Week 1 to Week 2. The results are presented in 
Table 4.3. 
Table 4.3: Benefit-Cost Ratio for Emotional Cost Factor Scenarios under Separation 
Anxiety Factor = 0.2 
Week Base Scenario 
1 
Scenario 
2 
Scenario 
3 
Scenario 
4 
Scenario 
5 
Week 0 4.07 4.07 4.07 4.07 4.07 4.07
Week 1 1.36 1.57 1.44 1.33 1.24 1.16
Week 2 0.79 1.05 0.88 0.74 0.63 0.54
Week 3 0.50 0.74 0.55 0.40 0.30 0.23
Week 4 0.35 0.60 0.38 0.24 0.16 0.11
Week 5 0.27 0.51 0.28 0.15 0.09 0.05
Week 6 0.21 0.45 0.21 0.10 0.05 0.02
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CHAPTER V:  SUMMARY AND CONCLUSIONS  
 In this chapter, we present the summary and conclusions from the research.  It is 
organized in three parts. The first part provides the summary of the study. The second part 
the study’s conclusions and lessons learned.  The final part presents recommendations for 
future research on the subject.  
5.1 Summary 
The problem this research focus was on assessing the economics of pain 
management in a terminally ill pet.  The importance of the problem rests on the challenges 
veterinarians face when dealing with pet owners whose pets have terminal illnesses.  
Because of their relationships with their pets, there are often difficulties in making 
objective decisions about treatment programs that are in the pet’s best interest.  It is not 
uncommon for pet owners to put their emotional pain of the impending death of their pet 
ahead of the humane treatment of the pet, which may in the case of terminally ill pets, be 
euthanasia.  The research sought, then, to develop a process to help veterinarians work with 
their clients to make these end-of-life decisions in the most economically sound manner, 
taking into consideration the medical costs of treatment and the emotional and subjective 
costs and values of the pet to the pet owner.   
The research used a benefit-cost ratio analysis as the economic decision support 
mechanism.  Benefit from owning a pet was defined as the monetary value the pet owner 
places on the pet.  There are numerous ways in which this value may be discovered 
“truthfully” from the pet owner. However, in this research it was assumed to be $1,000.  
Conceptually, this value was seen as a function of time: the longer the pet has been with its 
owner, then higher the value the owner would place on it. Cost comprised two major 
components: medical care cost, which involves medications and hospital staff services; and 
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emotional cost, which is a function of the debilitating effects of the pet’s sickness on the pet 
owner and his life. The simulated benefit-cost ratio of managing pet pain in the last six 
weeks of life used parameterized values of separation anxiety factor and emotional cost 
factor.   The independent simulations of separation anxiety and emotional cost factors 
showed that euthanasia was feasible as early as the second week and the decision seemed to 
be more sensitive to emotional cost factor than separation anxiety factor.   
The results suggest that the model is effective in helping veterinarians help their 
clients make more economical and humane choices using this simulation tool.  By allowing 
the clients to select their own parameters, they will be able to assess how their subjective 
perceptions and feelings translate into computer model results that help them make more 
objective choices.  The tool does not prevent them from recognizing their deep and 
complex relationship with their pet but it helps them to frame those relationships within the 
context of economic value.  
5.2 Conclusion and Suggestions for Future Research 
The fact that the non-pecuniary parameters produced similar decisions meant that the idea 
of parameterization to test model sensitivity was robust.  Using the benefit cost analysis 
and simulations as the methods allowed the data to be transformed from subjective data to 
objective data. 
Although each animal is unique in its medical needs and treatment, the information 
indicates that most pets are reaching a point where the discussion of euthanasia can be 
evaluated in the 2 to 5 week range after owner is aware of a condition being terminal.  The 
primary factor of separation anxiety prevents some owners from being able to emotionally 
make a humane decision, but as the emotional cost of daily nursing care, cost of time and 
medicine, and emotional cost of seeing pet declining in pain continues, euthanasia maybe 
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reconsidered.  A veterinarian must handle these situations very delicately and try to gage 
the families’ separation anxiety factors and emotional costs factors from their interactions 
with them. 
        The economic data here suggests the optimal time to discuss euthanasia is 2 to 5 
weeks after the pet is diagnosed with a terminal diagnosis, and is in severe pain, and has a 
life expectancy of 4-8 weeks.  Each case is unique and variables such as severity of 
condition, quality of life, emotional cost, and separation anxiety of the owner need 
consideration. 
 In talking to veterinarians around the country about this project, many veterinarians 
feel the FDA and pharmacy boards are overly focused on elimination of opioids (even 
small amounts for acute pain conditions) and not on better alternatives of pain relief as 
options for patients. Veterinarians need to review other modalities of pain relief.  
Reviewing alternative treatments and expected costs with clients, especially when limiting 
the more highly addictive (full mu agonist) narcotics.  Safer options may be needed if 
humans cannot stay away from these animal medications. Limiting the chance of human 
abuse is important to everyone.  
 The vast majority of veterinarians went into veterinary medicine to help animals 
and take the Hippocratic oath seriously to provide the best quality medicine that their 
clients can afford. Opioids have always been an option for those animal patients 
experiencing acute and chronic pain (severe arthritis and cancer patients most commonly). 
The altruistic value (the value of having patients in less pain) as well as the client’s attitude 
toward medications and their ability to follow treatment protocols needs to be assessed. 
When possible acute pain should be managed with only a short 3-7-day prescription, then 
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animals should be rechecked and medication only refilled if needed, and if the veterinarian 
feels the benefits outweigh the risks. Regardless of economic cost (this will include cost of 
ordering, prescribing, monitoring and complying with regulatory requirements) 
veterinarians want to provide the animal with the best medical care possible. Veterinarians 
treating chronic pain issues can discuss options such as non-steroidal medication, holistic 
products, muscle relaxers, cannabinoids, physical therapy, chiropractic and acupuncture 
procedures to help manage pain.  The cost of these additional therapies will ultimately have 
to be incurred by the owners or insurance companies. 
         Further research in the field of pain management should continue.  Scientific and 
medical research must develop safe medications/therapies for both humans and animals to 
control pain that will be cost effective for the average family. The addictive potential of 
these products needs to be better evaluated before they are released for wide spread usage.  
Veterinarians must carefully evaluate all aspect of a pet’s   medical situation before 
prescribing chronic pain medication. When the pet’s pain goes to a 3 or 4 on the pain scale 
veterinarians must consider the emotional cost factors and separation anxiety factor to 
determine the best time to have the discussion about if and when the owner might decide to 
discontinue treatment and elect euthanasia.   
 Despite the knowledge and advances in economics and veterinary medicine, each 
veterinarian must provide empathy and guidance for pet owners.  The variables of human 
nature will make it difficult to obtain perfect understanding and objective decisions in 
every case. 
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APPENDIX A  
 
Responses from seven veterinarians about their pain management protocols. The question 
was: 
Please rate the following pain medications for managing the pain of a pet with chronic pain, 
such as arthritis or cancer.  1 being the least effective, and 10 the most effective at reducing 
the pain level. 
1. Tramadol 
2. Fentanyl 
3. Gabapentin 
4. Prednisone 
5. Caprofen 
6. Chiropractic 
7. Acupuncture 
8. CBD - cannabis 
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APPENDIX B  
PAIN MEDICATION FOR CATS 
Drug Cat Dose (mg/kg) Notes 
Acetaminophen-Tylenol@ (Paracetamol) Contraindicated Small doses rapidly cause death in cats. 
Amantadine-Symmetrel@ 3.0-5.0 mg/kg PO q24 hrs This drug has not been evaluated for toxicity but is 
well tolerated in dogs and humans, with occasional 
side effects of agitation and GI irritation. May be a 
useful addition to NSAIDs in the treatment of 
chronic cancer pain conditions. Amantadine 
powder can be formulated to correct dose. 
Amitriptyline-Elavil@ 0.5-2.0 mg/kg PO q24 hrs This drug appears to be well tolerated for up to 12 
months of daily administration. Can be formulated 
into a dermal application. May be a useful addition 
to NSAIDs for treatment of chronic pain 
conditions. 
Aspirin 10 mg/kg PO q48 hrs Can cause significant GI ulceration. Do not use 
more that 3 days! 
Buprenorphine-Buprinex@ 0.02-0.03 mg/kg SL q8-12 hrs  Good way to provide postoperative analgesia at 
home. Feedback from owners indicates that after 
2-3 days dosing at this dose, anorexia develops. 
Smaller doses (5-10 µg/kg) may be more 
appropriate for “long-term” administration, 
especially in combination with other drugs. 
Butorphanol-Torbutrol@  Torbugesic@ 0.2-1.0 mg/kg PO q6 hrs Oral form after surgery may be beneficial. 
Generally considered to be a poor analgesic in cats 
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except for visceral pain; it to be useful as part of a 
multimodal approach to cancer pain therapy. 
Carprofen- Rimadyl@ Not enough data to enable 
recommendations for long-term 
administration. 
 
Fentanyl patch (transdermal) 2-5 µg/kg/hrs The patches may provide 5-7 days of analgesia in some cases and should be left on for longer than 3 
days. Following removal, the decay in plasma 
levels following patch removal is slow. 
Firocoxib-Previcox@ — Has not been reported in clinical cases, but it has a 
half-life of 8-12 hours in the cat, and at 3 mg/kg 
provided antipyretic effects in a pyrexia model. 
Flunixin.meglumine-Banamine@ 1 mg/kg PO daily for 7 days Daily dosing for 7 days results in increased rate of 
metabolism of the drug but a rise in liver enzymes, 
suggesting liver toxicity may be a problem with 
prolonged dosing. 
Gabapentin-Neurontin@ 10 mg/kg q12 hrs Appears to be particularly effective in chronic pain 
in cats where an increase in sensitivity has 
occurred, or where the pain appears to be 
excessive. 
Glucosamine/chondroitin sulphate 
combinations 
 15 mg/kg chondroitin sulphate PO 
q12-24 hrs 
May be associated with mild analgesic effects. 
Glucosamine/chondroitin sulphate combination 
with avocado/soya extracts 
  At labelled dose May be associated with mild analgesic effects. 
Ketoprofen-Orudis@ 1 mg/kg PO q24 hrs Probably well tolerated as pulse therapy for 
chronic pain, with a few days “rest” between 
treatments of approximately 5 days. Has also been 
used by some at 1 mg/kg every 3 days long term. 
Another approach has been to use 0.5 mg/kg daily 
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for 5 days (weekdays) followed by no drug over 
the weekend and repeated. 
Meloxicam-Metacam@ 0.01 mg/kg PO on day 1, followed 
by  
0.05 mg/kg PO daily for 4 days, 
then  
0.05 mg/kg every other day 
thereafter.  
Well received by cats due to its formulation as a 
honey syrup. Also, the drop formulation makes it 
very easy to gradually and accurately decrease the 
dose. Meloxicam should be dosed accurately using 
syringes. 
Morphine (oral liquid) 0.2-0.5 mg/kg PO every 6 to 8 
hours 
Best compounded into a palatable, flavored syrup; 
however, cats usually resent this medication. 
Morphine may not be as effective in cats as it is in 
dogs. 
Morphine (oral sustained release) Tablets too large for dosing cats. — 
Piroxicam-Feldene@ 1 mg/cat PO daily for a maximum 
of 7 days. If longer term try EOD 
Daily dosing for 7 days results in a slight increase 
in the half-life. 
Prednisolone 0.5-1.0 mg/kg PO q24 hrs Can be very effective. NOT to be combined with 
concurrent NSAID administration. 
Polysulfated glycosaminoglycans (PSGAGs; 
Adequan) 
5 mg/kg SQ twice weekly for 4 
weeks; then once weekly for 4 
weeks; then once monthly (other 
suggested regimens call for once 
weekly injections for 4 weeks, then 
once monthly). 
There is no evidence-based medicine that it 
provides any analgesic effect, but anecdotal 
information suggests improvement can be seen 
after a few injections. 
Robenacoxib-Onsior@ 1-2 mg/kg q24 hrs First NSAID that is a COX-2 inhibitor, has a short 
half-life, and demonstrates tissue selectivity. 
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Tepoxalin-Zubrin@ 5-10 mg/kg q24 hrs NSAID used long-term in cats, likely due to its 
short half-life (5 hours). 
Tolfenamic..acid-Clotam@ 4 mg/kg PO q24 hrs for 3days 
maximum 
 Has not been evaluated for chronic pain, but 
recent objective measurements demonstrate 
analgesia in the cat when administered at surgery 
time 
Tramadol-Ultram@ 1-2 mg/kg once to twice daily Main problem is dosing cats—the tablets are very 
bitter and hard to pill cats. 
   
Vedaprofen-Quadrisol@ 0.5 mg/kg q 24 hrs for 3 days NSAID not been evaluated for chronic pain but 
was evaluated for controlling pyrexia in upper 
respiratory infection, and for controlling 
postoperative pain following ovariohysterectomy. 
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APPENDIX C 
COMMON ABBREVIATIONS USED: 
 
 PO - By mouth;  
GI - gastrointestinal;  
NSAIDs - nonsteroidal anti-inflammatories;  
SL - sublingual;  
SQ - subcutaneous; 
 tid - three times a day;  
qid - four times a day;  
COX-2, cyclooxygenase-2.  
CSUTH – Colorado State University Teaching Hospital  
DEA – Drug Enforcement Agency,   
FDA Federal Drug Administration,  
PDMP- Prescription Drug Monitoring program 
 
 
